Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CAI

Caris Life Sciences Inc

Dec 08 • 04:00PM ET

28.36

-0.50 -1.73 %

Healthcare • Biotechnology • USA • NASD

Held by: ARKG IWR IWP ONEQ VTI IWF VB GURU FMED IWD

Index	-	P/E	-	EPS (ttm)	-2.43	Insider Own	59.13%	Shs Outstand	282.10M	Perf Week	8.87%
Market Cap	8.00B	Forward P/E	-	EPS next Y	-	Insider Trans	0.03%	Shs Float	115.32M	Perf Month	15.24%
Enterprise Value	7.67B	PEG	-	EPS next Q	0.01	Inst Own	37.37%	Short Float	4.46%	Perf Quarter	-16.47%
Income	-681.86M	P/S	12.33	EPS this Y	-	Inst Trans	3.96%	Short Ratio	3.94	Perf Half Y	-
Sales	649.06M	P/B	16.72	EPS next Y	-	ROA	-	Short Interest	5.15M	Perf YTD	1.29%
Book/sh	1.70	P/C	10.57	EPS next 5Y	-	ROE	-	52W High	42.50 -33.27%	Perf Year	-
Cash/sh	2.68	P/FCF	-	EPS past 3/5Y	- -	ROIC	-75.89%	52W Low	22.86 24.06%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	59.93%	Volatility	6.04% 6.40%	Perf 5Y	-
Dividend TTM	-	EV/Sales	11.82	EPS Y/Y TTM	-	Oper. Margin	-12.38%	ATR (14)	1.70	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.36	Sales Y/Y TTM	-	Profit Margin	-105.05%	RSI (14)	58.20	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	9.93	EPS Q/Q	126.22%	SMA20	11.51%	Beta	-	Target Price	38.50
Payout	-	Debt/Eq	0.89	Sales Q/Q	113.38%	SMA50	-0.33%	Rel Volume	1.69	Prev Close	28.86
Employees	-	LT Debt/Eq	0.88	Earnings	Nov 05 AMC	SMA200	-5.96%	Avg Volume	1.31M	Price	28.36
IPO	Jun 18, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	145.66% 24.58%	Trades		Volume	2,204,793	Change	-1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Initiated	Canaccord Genuity	Hold	$28
Jul-14-25	Initiated	Wolfe Research	Outperform	$32
Jul-14-25	Initiated	TD Cowen	Buy	$32
Jul-14-25	Initiated	JP Morgan	Overweight	$31
Jul-14-25	Initiated	Guggenheim	Buy	$32
Jul-14-25	Initiated	Evercore ISI	Outperform	$33
Jul-14-25	Initiated	Citigroup	Buy	$34
Jul-14-25	Initiated	BTIG Research	Buy	$38
Jul-14-25	Initiated	BofA Securities	Buy	$31

Today 09:55AM	Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-04-25 08:30AM	Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium (PR Newswire)
Dec-02-25 01:53PM	IP Oh No? Recent Stock Market Debuts Have Fizzled. (Barrons.com)
08:30AM	The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute (PR Newswire)
Nov-21-25 08:30AM	Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class (PR Newswire)
08:30AM	Loading…
Nov-17-25 08:30AM	Caris Life Sciences to Attend Q4 2025 Investor Conferences (PR Newswire)
Nov-05-25 04:05PM	Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (PR Newswire) -6.32% -15.75%
Nov-04-25 07:27AM	What To Expect From Caris Life Sciences Inc (CAI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 08:41AM	Caris Life Sciences announces collaborative new research on TET2 (TipRanks) +5.91%
Oct-29-25 08:30AM	Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response (PR Newswire)
Oct-23-25 08:30AM	Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025 (PR Newswire) +5.39%
Oct-14-25 08:30AM	Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025 (PR Newswire)
Oct-01-25 01:43PM	Caris Life Sciences, Inc. (CAI) Soars 81% YoY with $181M Q2 Revenue (Insider Monkey)
Sep-18-25 08:40AM	Strong Performance Lifted Caris Life Sciences (CAI) in Q2 (Insider Monkey)
Sep-11-25 11:17AM	Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test (Insider Monkey)
08:35AM	Loading…
08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks)
Aug-15-25 08:30AM	Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek (PR Newswire)
Aug-13-25 08:30AM	New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups (PR Newswire) +5.61%
Aug-12-25 04:05PM	Caris Life Sciences Reports Second Quarter 2025 Financial Results (PR Newswire) +7.45%
Aug-06-25 08:30AM	Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor (PR Newswire)
Aug-05-25 08:30AM	Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed (PR Newswire)
Jul-23-25 08:30AM	Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-22-25 08:30AM	Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis (PR Newswire) +7.07%
Jul-08-25 06:30AM	Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection (PR Newswire)
Jun-20-25 05:01AM	Caris Life Sciences indicated to open at $30, IPO priced at $21 per share (TipRanks)
Jun-18-25 02:50PM	This 'AI TechBio' company goes public as IPO demand spreads to biotech (MarketWatch)
01:37PM	The IPO Market Extends Its Comeback (Barrons.com)

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Denton John Russel	See Remarks	Nov 07 '25	Buy	24.09	4,184	100,793	9,184	Nov 10 08:12 AM
Spetzler David Baxley	President	Nov 07 '25	Buy	23.85	400	9,540	460,777	Nov 10 08:11 AM
PHILLIPS T DANNY	Director	Sep 11 '25	Option Exercise	2.44	100,000	244,000	116,129	Sep 12 04:29 PM
POSTE GEORGE	Director	Aug 11 '25	Option Exercise	2.44	125,000	305,000	359,754	Aug 13 08:07 PM
Spetzler David Baxley	President	Jun 20 '25	Option Exercise	2.44	75,000	183,000	558,668	Jun 23 06:41 PM
Denton John Russel	See Remarks	Jun 20 '25	Buy	21.00	7,500	157,500	123,591	Jun 23 06:34 PM
Brille Brian J	See Remarks	Jun 20 '25	Buy	21.00	30,000	630,000	162,428	Jun 23 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAI

Caris Life Sciences Inc

Upgrade your FINVIZ experience